Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NOV120401 (CKD-516) in Advanced Refractory Solid Tumors
NCT02300467Phase 1Unknown
- Sponsor
- National OncoVenture
- Start
- Dec 2014
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of valecobulin, sponsored by National OncoVenture. Primary endpoints: Number of Participants with Adverse Events at 40 weeks and Maximum Tolerated Dose / Recommended Phase 2 Dose at 40 weeks. Status: unknown.
02
Drugs
valecobulin
Beyond the preview
Go deeper on NCT02300467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02300467.